新型冠狀病毒感染疾病 (COVID-19) - 流行病學分析與預測:2020年6月
Coronavirus Disease 2019 - Epidemiology Analysis and Forecast - June 2020
|出版日期||內容資訊||英文 38 Pages
|新型冠狀病毒感染疾病 (COVID-19) - 流行病學分析與預測:2020年6月 Coronavirus Disease 2019 - Epidemiology Analysis and Forecast - June 2020|
|出版日期: 2020年06月30日||內容資訊: 英文 38 Pages||
本報告提供新型冠狀病毒感染疾病 (COVID-19) 調查分析，目前流行病學情形，預測，主要市場預測相關的系統性資訊。
The pandemic's epicenters have shifted to Latin America, India, Pakistan, and South Africa. COVID-19 is mainly affecting the dense populous and poorer regions of these countries. As a result, the global daily confirmed cases are increasing at a higher pace than before.
The US continues to be the most affected country globally, reaching close to 2.5 million cases.
The US reported the highest number of new daily cases on 26 June since the start of the pandemic. Chile moves up ahead of Spain. Brazil has now reported more than 1 million total confirmed cases of COVID-19. Mexico is now ranked 11th among the top most affected countries.
The report covers current epidemiology situation, forecast, and analysis of COVID-19 in June 2020, including forecast for key markets.The report will be updated on a monthly basis.
The report provide forecast for peak-week and return-to-normal week that will help the reader plan in this uncertain time, and highlights important populations and regions most affected by the outbreak.
Latin America has had a slow start but has already shown concerning trends, and it has not yet reached peak numbers.
There is a risk of a COVID-19 surge in India as the country's outlook remains uncertain.
Strict lockdown policies in Peru have done little to curb the spread of COVID-19.
Areas of Improvement
New Zealand was declared free of COVID-19 after 100 days.
Positive COVID-19 test rates are steadily declining in the US.
Despite the recent surge in the daily confirmed cases of COVID-19 in India, the average fatality rate is relatively low.
Testing availability and criteria differ significantly between countries.
The number of reported confirmed cases in all countries underestimates the actual number of infected people.
Mortality reporting is not standardized.
Antibody testing has limitations in accuracy and usefulness.
Minority ethnic groups are two to three times more likely to die of COVID-19 in the UK and US.
More chronic kidney disease patients are likely to go undiagnosed due to reduced primary care access during the pandemic.
COVID-19 increases the risk of mortality in patients with Hodgkin lymphoma.
Viral infection may increase acute myeloid leukemia risk.